Next Article in Journal
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
Previous Article in Journal
The Contribution of JAK2 46/1 Haplotype in the Predisposition to Myeloproliferative Neoplasms
 
 
Article

Article Versions Notes

Int. J. Mol. Sci. 2022, 23(20), 12574; https://doi.org/10.3390/ijms232012574
Action Date Notes Link
article xml file uploaded 20 October 2022 10:10 CEST Original file -
article xml uploaded. 20 October 2022 10:10 CEST Update https://www.mdpi.com/1422-0067/23/20/12574/xml
article pdf uploaded. 20 October 2022 10:10 CEST Version of Record https://www.mdpi.com/1422-0067/23/20/12574/pdf
article supplementary file uploaded. 20 October 2022 10:10 CEST - https://www.mdpi.com/1422-0067/23/20/12574#supplementary
article html file updated 20 October 2022 10:11 CEST Original file -
article html file updated 28 February 2023 19:00 CET Update -
article html file updated 1 March 2023 23:06 CET Update https://www.mdpi.com/1422-0067/23/20/12574/html
Back to TopTop